NCT05072600View on ClinicalTrials.gov

Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 7, 2021

Primary Completion Date

December 7, 2024

Study Completion Date

November 1, 2029

Conditions
Bladder CancerBladder NeoplasmsBladder TumorsUrinary Bladder CancerNeoplasms, Bladder
Interventions
DRUG

Pembrolizumab

pembrolizumab 200 mg Q3W

Trial Locations (1)

100034

RECRUITING

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER